First-line treatment of metastatic NSCLC MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Sponsors
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Has a histologically or cytologically confirmed diagnosis of Stage IV (T any, N any, M1a, M1b, M1c - AJCC eighth Edition) squamous or nonsquamous NSCLC 2. Has measurable disease based on RECIST 1.1, as determined by the local site assessment 3. Has provided tumor tissue (post diagnosis of metastatic disease is preferred) for determination of PD-L1 status before randomization 4. Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy (documentation of the absence of tumor-activating EGFR mutations [eg, DEL19 or L858R], AND absence of ALK and ROS1 gene rearrangements) 5. Has not received prior systemic treatment for metastatic NSCLC 6. Is male or female, from =18 years of age inclusive, at the time of signing the informed consent 7. Has an ECOG PS of 0 or 1 assessed within 7 days before randomization 8. Has a life expectancy of at least 3 months 9. If male, agrees to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention is as follows: • Chemotherapy: at least 95 days from the last dose • Refrain from donating sperm PLUS either: • Abstains from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent OR • Uses contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause, documented from the site personnel’s review of the participant’s medical records, medical examination, or medical history interview as detailed below: - Uses a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant - Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed 10. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: • Not a WOCBP OR • Is a WOCBP and: - Uses a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The length of time required to continue contraception for each study intervention is as follows: ? MK-7684A/pembrolizumab: 120 days ? Chemotherapy: 180 days - The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent tha
Exclusion criteria
Exclusion criteria: 1. Known additional malignancy that is progressing or has required active treatment within the past 3 years 2. Known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention. Participants with asymptomatic brain metastases (ie, no neurological symptoms, no requirements for corticosteroids, no or minimal surrounding edema, and no lesion >1.5 cm) may participate 3. Severe hypersensitivity (=Grade 3) to MK-7684, MK-7684A, pembrolizumab, chemotherapy components, and/or any of its excipients 4. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication 5. Active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed 6. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease 7. Active infection requiring systemic therapy 8. Known history of HIV infection. No HIV testing is required unless mandated by local health authority 9. Has a known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection 10. History or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator 11. Known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study 12. Received prior therapy with an anti-TIGIT, anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137) 13. Received prior systemic anticancer therapy for metastatic disease 14. If the participant had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the operation before starting study intervention 15. Received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis 16. Received radiation therapy to the lung that is >30 Gray within 6 months of the first dose of study intervention 17. Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed 18. Is unable to interrupt aspirin or other NSAIDs, other than an aspirin dose =1.3 g/day, for a 5-day period (8-day period for long-acting agents, such as piroxicam) 19. Is unable or unwilling to take folic acid or vitamin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: 1. To compare MK-7684A in combination with chemotherapy to pembrolizumab in combination with chemotherapy with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR) 2. To compare MK-7684A in combination with chemotherapy to pembrolizumab in combination with chemotherapy with respect to Overall Survival (OS);Secondary Objective: 1. To evaluate MK-7684A in combination with chemotherapy to pembrolizumab in combination with chemotherapy with respect to Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR 2. To evaluate the mean change from baseline in global health status/quality of life (QoL), physical functioning, dyspnea, cough, and chest pain for MK-7684A in combination with chemotherapy compared to pembrolizumab in combination with chemotherapy 3. To evaluate the Time to True Deterioration (TTD) in global health status/QoL, physical functioning, dyspnea, cough, and chest pain for MK-7684A in combination with chemotherapy compared to pembrolizumab in combination with chemotherapy 4. To evaluate the safety and tolerability of MK-7684A in combination with chemotherapy compared to pembrolizumab in combination with chemotherapy 5. To evaluate DOR per RECIST 1.1 as assessed by BICR for MK-7684A plus chemotherapy compared to pembrolizumab plus chemotherapy;Primary end point(s): 1. Progression-Free Survival (PFS) 2. Overall Survival (OS);Timepoint(s) of evaluation of this end point: 1. Up to approximately 33 months 2. Up to approximately 42 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Objective Response Rate (ORR) 2. Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) 3. Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 4. Change from Baseline in Dyspnea Score (Item 8) on the EORTC QLQ-C30 5. Change from Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13) 6. Change from Baseline in Chest Pain Score (Item 40) on the EORTC QLQ- LC13 7. Time to Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the EORTC QLQ-C30 8. TTD in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ- C30 9. TTD in Dyspnea Score (Item 8) on the EORTC QLQ-C30 10. TTD in Cough Score (Item 31) on the EORTC QLQ-LC13 11. TTD in Chest Pain Score (Item 40) on the EORTC QLQ-LC13 12. Number of Participants Who Experienced One or More Adverse Events (AEs) 13. Number of Participants Who Discontinued Study Intervention Due to an AE 14. Duration of Response (DOR);Timepoint(s) of evaluation of this end point: 1. Up to approximately 42 months 2. Baseline and Up to approximately 42 months 3. Baseline and Up to approximately 42 months 4. Baseline and Up to approximately 42 months 5. Baseline and Up to approximately 42 months 6. Baseline and Up to approximately 42 months 7. Up to approximately 42 months 8. Up to approximately 42 months 9. Up to approximately 42 months 10. Up to approximately 42 months 11. Up to approximately 42 months 12. Up to approximately 42 months 13. Up to approximately 42 months 14. Up to approximately 42 months | — |
Countries
Argentina, Austria, Brazil, Chile, China, Colombia, France, Germany, Israel, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
Contacts
Public ContactInvestigación clínica
Merck Sharp & Dohme de España SA
Outcome results
None listed